相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Hongwei Lv et al.
CELL METABOLISM (2021)
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Christine M. Heske
FRONTIERS IN ONCOLOGY (2020)
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Ubaldina Galli et al.
FRONTIERS IN PHARMACOLOGY (2020)
Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p
Xiaoping Li et al.
CELL DEATH & DISEASE (2019)
The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges
Maria Dalamaga et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer
Xingsen Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells
Bin Zhang et al.
ONCOLOGY LETTERS (2018)
2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer
Xiaojin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis
Antonio Lucena-Cacace et al.
ONCOTARGET (2017)
Understanding the checkpoint blockade in lung cancer immunotherapy
Maria Giovanna Dal Bello et al.
DRUG DISCOVERY TODAY (2017)
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model
Giovanna Sociali et al.
ONCOTARGET (2016)
NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy
Yue Yang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2016)
Using DNA devices to track anticancer drug activity
Dimithree Kahanda et al.
BIOSENSORS & BIOELECTRONICS (2016)
Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer
Nam Bui et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities
Hang Chen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
Jinhong Bai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Deoxynyboquinones as NQO1-Activated Cancer Therapeutics
Elizabeth I. Parkinson et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation
Caroline S. Breton et al.
BIOCHIMIE (2015)
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
Deepak Sampath et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid
Jacqueline M. Tarrant et al.
TOXICOLOGY MECHANISMS AND METHODS (2015)
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by beta-lapachone
Z. Moore et al.
CELL DEATH & DISEASE (2015)
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid
Jacqueline M. Tarrant et al.
TOXICOLOGY MECHANISMS AND METHODS (2015)
NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Giuseppina Stefano et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2015)
Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase
Tanja S. Zabka et al.
TOXICOLOGICAL SCIENCES (2015)
2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1)
Jinlei Bian et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Polypharmacology: Challenges and Opportunities in Drug Discovery
Andrew Anighoro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Efficient NQO1 Substrates are Potent and Selective Anticancer Agents
Elizabeth I. Parkinson et al.
ACS CHEMICAL BIOLOGY (2013)
Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
By Fabrizio Montecucco et al.
CURRENT DRUG TARGETS (2013)
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
Ubaldina Galli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Polypharmacology - Foe or Friend?
Jens-Uwe Peters
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models
Thomas O'Brien et al.
NEOPLASIA (2013)
Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
Fariz Nurwidya et al.
CANCER RESEARCH AND TREATMENT (2012)
The NAD metabolome - a key determinant of cancer cell biology
Alberto Chiarugi et al.
NATURE REVIEWS CANCER (2012)
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas
Uffe Hogh Olesen et al.
APMIS (2011)
Targeting cancer metabolism: a therapeutic window opens
Matthew G. Vander Heiden
NATURE REVIEWS DRUG DISCOVERY (2011)
Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
David M. Goldstein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector
Albena T. Dinkova-Kostova et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
Anne von Heideman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Nampt: linking NAD biology, metabolism and cancer
Antje Garten et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
Enzymology of mammalian NAD metabolism in health and disease
Giulio Magni et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
Kyle Holen et al.
INVESTIGATIONAL NEW DRUGS (2008)
An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone
Erik A. Bey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents
Javed A. Khan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol
Gad Asher et al.
BIOCHEMISTRY (2006)
分享论文
